Welcome to the Lab Report, a monthly news briefing designed to highlight recent news in the clinical laboratory industry. As champions for clinical labs, we want to spread news about the great work being done in healthcare facilities and clinical settings throughout the United States.
Check back often to find out about award winners, staff and manager promotions, facility expansions, policy and regulatory updates, association news and more. We hope you will share this content with your fellow MLPs, managers and friends.
To help us continue to spread news about the lab, keep our team updated by emailing press releases, photos and short articles to us using the Contact Us tools on this site.
SCCM Data Presentation on Difficult-to-Treat Infections
Theravance Biopharma recently reported new interim data from the Company’s ongoing Telavancin Observational Use Registry (TOUR) study in an oral presentation at the Society of Critical Care Medicine’s (SCCM) 46th Critical Care Congress. TOUR is designed to assess how VIBATIV (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings. The presented findings, which focused on a subset of registry patients with diagnoses of bacteremia or infective endocarditis (IE) (n=45), demonstrated positive clinical responses in 64.4% of patients, with 6.7% of patients failing treatment and 28.9% considered non-evaluable. Positive clinical response was defined as cure or improvement leading to step-down oral therapy.
The SCCM 46th Critical Care Congress was held in Honolulu, HI on January 20-25, 2017. As of September 30, 2016, 593 patients had been enrolled in the TOUR study, with 45 of those having diagnoses of bacteremia or IE. In addition to clinical response results for these 45 patients, researchers reported that the pathogens causing bacteremia or IE in TOUR patients included methicillin-resistant Staphylococcus aureus (S. aureus) or MRSA (53% of patients), methicillin-susceptible S. aureus or MSSA (13%), coagulase negative staphylococci (9%), and enterococcus (7%), among others.
Baylor Scott & White Health Implement Laboratory Data Analytics
Baylor Scott & White Health has implemented Performance Insight from Visiun. As part of this partnership, Baylor Scott & White has installed the system for their hospital laboratories. Access to laboratory analytics will enable laboratory management to take action to increase efficiency in the laboratory and implement measures for process improvement to continue to meet the highest of standards.
Compatible with every major LIS on the market, Performance Insight provides laboratory management with business intelligence and data analytics to help their teams monitor key service commitments and improve workflow, quality and financial performance. Laboratories can visualize everything that is happening in the lab on a daily basis including turnaround time, quality, productivity/workflow, blood product utilization, test utilization and more.
Omicia Joins Cancer Moonshot’s Blood Profiling Atlas
Omicia, Inc. was selected to join the Cancer Moonshot’s Blood Profiling Atlas in Cancer (Blood PAC) consortium. In joining Blood PAC, Omicia is demonstrating its commitment to advancing cancer genetics research and extending patients’ lives. The Blood PAC was formed in October 2016 in alignment with Vice President Joe Biden’s Cancer Moonshot initiative. The scientists in Blood PAC will quickly advance the study of liquid biopsy samples, and develop safe and effective patient blood profiling diagnostic technologies.
Omicia is supporting the Cancer Moonshot’s Blood PAC by providing leading clinical informatics tools for the analysis of circulating tumor DNA from liquid biopsy samples. Other Blood PAC members include AstraZeneca, Celgene, CytoLumina Technologies Corp., Eli Lilly and Company, Epic Sciences, Foundation Medicine, Genentech, Genomic Health, Guardant Health, Indivumed, MSKCC, Novartis, Open Commons Consortium, Personal Genome Diagnostics, Pfizer, Provista Diagnostics, Seven Bridges, Sysmex Inostics, Thermo Fisher Scientific, the University of Michigan and the University of Southern California.
AMGA Welcomes New Members to Board of Directors
AMGA, an association representing medical groups and integrated systems of care, recently announced the addition of three new members to its board of directors, beginning their tenure in January 2017. The AMGA Board of Directors represents the leadership of some of the association’s most prominent member medical groups. Joining the AMGA Board are the following:
Mark DeRubeis, MBA, chief executive officer, Premier Medical Associates—DeRubeis is the chief executive officer at Premier Medical Associates, the largest multispecialty practice in the Greater Pittsburgh area. Shane Peng, MD, FAAFP, president, SSM Health—Peng joined SSM Health in 2013. As president of physician and ambulatory services, Dr. Peng works to ensure physicians across SSM Health’s Illinois, Missouri, Oklahoma, and Wisconsin service areas are fully engaged in the system’s move to integrated delivery networks. Larry Tatum, MD, chief executive officer, Privia Medical Group—Tatum has experienced the value and high success of a multispecialty group governed and led by physicians.
API Awards Ninth Year of Medical Laboratory Science Scholarships
An appreciation for scientific advancements flows strongly among the winners of the 2016 American Proficiency Institute (API) scholarships. The American Proficiency Institute is one of the largest proficiency testing providers in the world, serving nearly 20,000 laboratories. Five students enrolled in medical laboratory science programs across the United States won the awards to further their education.
API awarded $2,000 scholarships to: Brittany Isaac, a senior at the University of Alabama-Birmingham; Craig Kleehamer, a senior at Indiana University; Emily Matthys, a senior at Marshfield Labs Medical Laboratory Science Program; Ellen Panetto, a junior at the University of Massachusetts – Lowell; and Ariel Tompsett, a senior at the Nebraska Methodist Hospital Medical Laboratory Science Program.
uniQure Appoints Matthew Kapusta as CEO
Human gene therapy company uniQure recently announced that its board of directors has unanimously approved the appointment of Matthew Kapusta as chief executive officer (CEO), effective immediately. Kapusta had served as interim CEO since September 2016 and as Chief Financial Officer since January 2015. Prior to joining uniQure, he was Senior Vice President at AngioDynamics from 2011 to 2014, responsible for business development, strategic planning and national accounts. Prior to this, he served as vice president, Finance for Smith & Nephew Orthopaedics.
Kapusta’s career also includes more than a decade of investment banking experience focused on emerging life sciences companies. He was managing director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber. Kapusta holds a Master of Business Administration from New York University’s Stern School of Business, a Bachelor of Business Administration from University of Michigan’s Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.